Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(16.0%),OrbiMed Israel GP Ltd.(16.0%)等
Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(18.3%),OrbiMed Israel GP Ltd.(18.3%)等
Chemomab Therapeutics | 4:持股变动声明-董事 Darvish Nissim
Chemomab Therapeutics | 4:持股变动声明-董事 Quigley Jill M.
Chemomab Therapeutics | 4:持股变动声明-首席财务官 Fatal Sigal
Chemomab Therapeutics | 3:首次持股声明-首席财务官 Fatal Sigal
Chemomab Therapeutics | 4:持股变动声明-董事 Moses Alan Charles
Chemomab Therapeutics | 4:持股变动声明-董事 Nicaise Claude
Chemomab Therapeutics | 4:持股变动声明-董事 Cohen Neil Harris
Chemomab Therapeutics | 4:持股变动声明-董事 Darvish Nissim
Chemomab Therapeutics | 4:持股变动声明
Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(19.7%),OrbiMed Israel GP Ltd.(19.7%)
Chemomab Therapeutics | 4:持股变动声明
Chemomab Therapeutics | 4:持股变动声明
Chemomab Therapeutics | 4:持股变动声明
Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Adi Mor(6.4%),Kobi George(6.4%)
Chemomab Therapeutics | 3:首次持股声明-高管 Frankel Matthew Bejosa
Chemomab Therapeutics | 3:首次持股声明-董事 Quigley Jill M.
Chemomab Therapeutics | 4:持股变动声明
Chemomab Therapeutics | 4:持股变动声明
暂无数据